financetom
Business
financetom
/
Business
/
Bunge receives China regulatory approval for Viterra deal
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Bunge receives China regulatory approval for Viterra deal
Jun 13, 2025 11:15 AM

CHICAGO (Reuters) -Global agribusiness Bunge Global SA ( BG ) has received regulatory approval from China for its acquisition of grain handler Viterra and expects to close the $34 billion deal "on or around July 2," the company said in a statement on Friday.

The deal, first announced in 2023, will create a global crop trading and processing giant closer in scale to chief rivals Archer-Daniels-Midland and Cargill.

Approval from China was the final regulatory approval Bunge needed to finalize the deal after gaining approvals from regulators in Canada, the European Union and other markets.

"Achieving this regulatory milestone is a significant step forward and clears the way for closing of the transaction. This approval underscores the strategic rationale behind bringing Bunge and Viterra together to create a premier global agribusiness company," CEO Greg Heckman said in an emailed statement.

Bunge shares were up 6.1% at midday on Friday.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Taoping Says July Total Contract Revenue Value Rises 30%
Taoping Says July Total Contract Revenue Value Rises 30%
Aug 12, 2024
09:15 AM EDT, 08/12/2024 (MT Newswires) -- Taoping ( TAOP ) said Monday that its total contract revenue value rose 30% in July from a year earlier to about 27.4 million Chinese renminbi ($3.8 million). The technology company attributed the increase to strong demand for its artificial intelligence-based products. Taoping ( TAOP ) shares were nearly 9% higher in premarket...
Delay Hits Humacyte's Bioengineered Human Tissue Implant For Vascular Trauma Injuries, FDA Extends Time To Review
Delay Hits Humacyte's Bioengineered Human Tissue Implant For Vascular Trauma Injuries, FDA Extends Time To Review
Aug 12, 2024
Friday, the FDA announced it would require additional time to complete its review of Humacyte Inc.’s Biologic License Application (BLA) for the acellular tissue-engineered vessel (ATEV) in the vascular trauma indication. The ATEV trauma program BLA was submitted to the FDA in December 2023, and the FDA granted a Priority Review in February 2024 and assigned a PDUFA date of...
Bird Construction Selected for Five Projects Exceeding $575 Million
Bird Construction Selected for Five Projects Exceeding $575 Million
Aug 12, 2024
09:19 AM EDT, 08/12/2024 (MT Newswires) -- Bird Construction ( BIRDF ) , whose shares jumped 3.7% on Friday, said on Monday that it has been selected for five projects with a combined value of more than $575 million. These include multi-year mine infrastructure work in Eastern Canada and three long-term care projects and a multi-building institutional project in Western...
Starbucks, Elliott in talks over on a settlement, CNBC reports
Starbucks, Elliott in talks over on a settlement, CNBC reports
Aug 12, 2024
Aug 12 (Reuters) - Starbucks ( SBUX ) and activist investor Elliott Management are talking about a settlement, CNBC reported on Monday, citing sources. ...
Copyright 2023-2025 - www.financetom.com All Rights Reserved